Clinical Trials Logo

Recurrent Gliosarcoma clinical trials

View clinical trials related to Recurrent Gliosarcoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03360708 Completed - Clinical trials for Recurrent Glioblastoma

Vaccine Therapy in Treating Patients With Recurrent Glioblastoma

Start date: November 27, 2013
Phase: Early Phase 1
Study type: Interventional

This pilot early phase I trial studies the side effects of vaccine therapy in treating patients with glioblastoma that has come back. Vaccines made from a person's white blood cells mixed with tumor proteins from another person's glioblastoma tumors may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy may work better in treating patients with glioblastoma.

NCT ID: NCT00883298 Completed - Clinical trials for Recurrent Glioblastoma Multiforme

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

Start date: April 2009
Phase: Phase 2
Study type: Interventional

Primary objective - to determine the 6-month progression free survival (PFS) of adult patients with recurrent glioblastoma multiforme/gliosarcoma treated with bi-weekly temozolomide plus (Avastin) bevacizumab. Secondary objectives - to determine radiographic response including specialized MRI sequences, safety and overall survival of adult patients with with recurrent glioblastoma multiforme/gliosarcoma treated with bi-weekly temozolomide plus bevacizumab (Avastin). Additionally, tumor DNA (MGMT) analysis as it relates to survival will be evaluated.